Stay updated with breaking news from Icahn School. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
"Our findings offer a promising path for developing new treatments," the researchers said.
In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.
Chemical toxins are everywhere — in our water, food, air and soil. Exposure to those toxins during pregnancy can create serious health issues in elementary school children that can affect